Vascular targeting agents as cancer therapeuticsTHORPE, Philip E.Clinical cancer research. 2004, Vol 10, Num 2, pp 415-427, issn 1078-0432, 13 p.Article

Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapyRAN, Sophia; THORPE, Philip E.International journal of radiation oncology, biology, physics. 2002, Vol 54, Num 5, pp 1479-1484, issn 0360-3016, 6 p.Conference Paper

Increased exposure of anionic phospholipids on the surface of tumor blood vesselsRAN, Sophia; DOWNES, Amber; THORPE, Philip E et al.Cancer research (Baltimore). 2002, Vol 62, Num 21, pp 6132-6140, issn 0008-5472, 9 p.Article

Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserineXIANMING HUANG; DAN YE; THORPE, Philip E et al.Vaccine. 2011, Vol 29, Num 29-30, pp 4785-4793, issn 0264-410X, 9 p.Article

Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipidsJIN HE; LUSTER, Troy A; THORPE, Philip E et al.Clinical cancer research. 2007, Vol 13, Num 17, pp 5211-5218, issn 1078-0432, 8 p.Article

Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigenXIANMING HUANG; BENNETT, Mary; THORPE, Philip E et al.The Prostate. 2004, Vol 61, Num 1, pp 1-11, issn 0270-4137, 11 p.Article

A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in miceXIANNFING HUANG; BENNETT, Mary; THORPE, Philip E et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4408-4416, issn 0008-5472, 9 p.Article

Generation and characterization of recombinant vascular targeting agents from hybridoma cell linesGOTTSTEIN, Claudia; WELS, Winfried; OBER, Bertram et al.BioTechniques. 2001, Vol 30, Num 1, pp 190-200, issn 0736-6205, 7 p.Article

Targeting anionic phospholipids on tumor blood vessels and tumor cellsTHORPE, Philip E.Thrombosis research. 2010, Vol 125, issn 0049-3848, S134-S137, SUP2Conference Paper

Vascular endothelial growth factor and vascular targeting of solid tumorsBREKKEN, Rolf A; THORPE, Philip E.Anticancer research. 2001, Vol 21, Num 6B, pp 4221-4229, issn 0250-7005Article

The angiogenic vascular endothelial growth factor/ flk-1(KDR) receptor pathway in patients with endometrial carcinoma: prognostic and therapeutic implicationsGIATROMANOLAKI, Alexandra; SIVRIDIS, Efthimios; BREKKEN, Rolf et al.Cancer. 2001, Vol 92, Num 10, pp 2569-2577, issn 0008-543XArticle

The angiogenic pathway 'vascular endothelial growth factor/flk-1 (KDR)-receptor' in rheumatoid arthritis and osteoarthritisGIATROMANOLAKI, Alexandra; SIVRIDIS, Efthimios; ATHANASSOU, Nick et al.Journal of pathology. 2001, Vol 194, Num 1, pp 101-108, issn 0022-3417Article

Phosphatidylserine-Targeted Molecular Imaging of Tumor Vasculature by Magnetic Resonance ImagingHELING ZHOU; STAFFORD, Jason H; HALLAC, Rami R et al.Journal of biomedical nanotechnology (Print). 2014, Vol 10, Num 5, pp 846-855, issn 1550-7033, 10 p.Article

Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in miceBREKKEN, Rolf A; OVERHOLSER, Jay P; STASTNY, Victor A et al.Cancer research (Baltimore). 2000, Vol 60, Num 18, pp 5117-5124, issn 0008-5472Article

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumorsYAYUN LIANG; BESCH-WILLIFORD, Cynthia; BENAKANAKERE, Indira et al.Breast cancer research and treatment. 2011, Vol 125, Num 2, pp 407-420, issn 0167-6806, 14 p.Article

Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sitesPING GUO; LI XU; CAVENEE, Webster K et al.Cancer research (Baltimore). 2001, Vol 61, Num 23, pp 8569-8577, issn 0008-5472Article

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid TumorsGERBER, David E; STOPECK, Alison T; WONG, Lucas et al.Clinical cancer research (Print). 2011, Vol 17, Num 21, pp 6888-6896, issn 1078-0432, 9 p.Article

Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed PhosphatidylserineJENNEWEIN, Marc; LEWIS, Matthew A; ANTICH, Peter P et al.Clinical cancer research. 2008, Vol 14, Num 5, pp 1377-1385, issn 1078-0432, 9 p.Article

Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF₁₂₁/rGelMOHAMEDALI, Khalid A; POBLENZ, Ann T; SIKES, Charles R et al.Cancer research (Baltimore). 2006, Vol 66, Num 22, pp 10919-10928, issn 0008-5472, 10 p.Article

Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in miceRAN, Sophia; JIN HE; XIANMING HUANG et al.Clinical cancer research. 2005, Vol 11, Num 4, pp 1551-1562, issn 1078-0432, 12 p.Article

Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancerSTEPHAN, Susann; DATTA, Kaustubh; ENFENG WANG et al.Clinical cancer research. 2004, Vol 10, Num 20, pp 6993-7000, issn 1078-0432, 8 p.Article

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer modelWEI ZHANG; RAN, Sophia; SAMBADE, M et al.Angiogenesis (London). 2002, Vol 5, Num 1-2, pp 35-44, issn 0969-6970, 10 p.Article